Biogen buys in to molecular glues with Neomorph deal worth up to $1.45B

Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go after tough targets in Alzheimer’s and rare neurological and immunological diseases, the company announced in an Oct. 29 release.